BR112015025390A2 - Composição, métodos para isolar célula tronco, para tratar um indivíduo e um paciente, para reduzir um depósito de gordura, para dissociar um tecido e uma matriz de proteína, para tratar ou curar uma cicatriz ou uma ferida, e para isolar células ilhotas, vetor de expressão, composição farmacêutica, formulação de liberação temporizada, e, kit - Google Patents

Composição, métodos para isolar célula tronco, para tratar um indivíduo e um paciente, para reduzir um depósito de gordura, para dissociar um tecido e uma matriz de proteína, para tratar ou curar uma cicatriz ou uma ferida, e para isolar células ilhotas, vetor de expressão, composição farmacêutica, formulação de liberação temporizada, e, kit

Info

Publication number
BR112015025390A2
BR112015025390A2 BR112015025390A BR112015025390A BR112015025390A2 BR 112015025390 A2 BR112015025390 A2 BR 112015025390A2 BR 112015025390 A BR112015025390 A BR 112015025390A BR 112015025390 A BR112015025390 A BR 112015025390A BR 112015025390 A2 BR112015025390 A2 BR 112015025390A2
Authority
BR
Brazil
Prior art keywords
mmp
isolating
composition
dissociating
pharmaceutical composition
Prior art date
Application number
BR112015025390A
Other languages
English (en)
Portuguese (pt)
Inventor
Zylberberg Claudia
B Fields Gregg
Original Assignee
Zylberberg Claudia
B Fields Gregg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zylberberg Claudia, B Fields Gregg filed Critical Zylberberg Claudia
Publication of BR112015025390A2 publication Critical patent/BR112015025390A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24017—Stromelysin 1 (3.4.24.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24024—Gelatinase A (3.4.24.24), i.e. matrix metalloproteinase 2 or MMP2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24034—Neutrophil collagenase (3.4.24.34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
BR112015025390A 2013-04-05 2014-04-04 Composição, métodos para isolar célula tronco, para tratar um indivíduo e um paciente, para reduzir um depósito de gordura, para dissociar um tecido e uma matriz de proteína, para tratar ou curar uma cicatriz ou uma ferida, e para isolar células ilhotas, vetor de expressão, composição farmacêutica, formulação de liberação temporizada, e, kit BR112015025390A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808861P 2013-04-05 2013-04-05
PCT/US2014/033009 WO2014165780A2 (en) 2013-04-05 2014-04-04 Matrix metalloproteinases and uses thereof

Publications (1)

Publication Number Publication Date
BR112015025390A2 true BR112015025390A2 (pt) 2017-08-29

Family

ID=51659357

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025390A BR112015025390A2 (pt) 2013-04-05 2014-04-04 Composição, métodos para isolar célula tronco, para tratar um indivíduo e um paciente, para reduzir um depósito de gordura, para dissociar um tecido e uma matriz de proteína, para tratar ou curar uma cicatriz ou uma ferida, e para isolar células ilhotas, vetor de expressão, composição farmacêutica, formulação de liberação temporizada, e, kit

Country Status (15)

Country Link
US (1) US20160053250A1 (cg-RX-API-DMAC7.html)
EP (2) EP2981276A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016520550A (cg-RX-API-DMAC7.html)
KR (1) KR20160006694A (cg-RX-API-DMAC7.html)
CN (1) CN105246500A (cg-RX-API-DMAC7.html)
AU (1) AU2014248002A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015025390A2 (cg-RX-API-DMAC7.html)
CA (1) CA2908739A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150603A (cg-RX-API-DMAC7.html)
HK (1) HK1221405A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015014053A (cg-RX-API-DMAC7.html)
PH (1) PH12015502306A1 (cg-RX-API-DMAC7.html)
RU (1) RU2015147878A (cg-RX-API-DMAC7.html)
SG (1) SG11201508199QA (cg-RX-API-DMAC7.html)
WO (1) WO2014165780A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105412916B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗乳腺癌的组合物及其用途
CN105412917B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗实体瘤的抗癌组合物及其用途
CN105477628B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 抗癌组合物及其用途
CN105477627B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 治疗前列腺癌的组合物及其用途
WO2017038473A1 (ja) * 2015-08-28 2017-03-09 天野エンザイム株式会社 エンドトキシン低減サーモリシン
CN105907840A (zh) * 2016-03-29 2016-08-31 苏州大学 单细胞水平检测mmp酶活性的方法
US10137179B2 (en) 2016-05-18 2018-11-27 Hyalo Technologies, LLC Composition and method of preparation of protease microparticulate slow release preparation
CN108451981B (zh) * 2018-04-21 2019-07-23 江西汉氏联合干细胞科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
WO2020132608A1 (en) * 2018-12-20 2020-06-25 The Steadman Clinic And Steadman Philippon Research Institute Decellularized tendon matrix methods and uses thereof
CN114377150B (zh) * 2021-12-29 2023-10-13 中山大学南昌研究院 一种mmp酶敏感胎盘微环境和肿瘤微环境靶向载体及其制备方法和应用
CN116549325B (zh) * 2022-01-27 2025-07-29 南京大学 一种组合物、其制备方法、制剂及应用
CN119530138B (zh) * 2024-12-05 2026-01-30 中国肉类食品综合研究中心 一种用于工业化细胞解离的多酶制剂及其使用方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5770691A (en) * 1995-06-05 1998-06-23 Regents Of The University Of Minnesota Discriminatory substrates for MMP hydrolysis
JP4335316B2 (ja) 1996-09-19 2009-09-30 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン アルギネートまたは修飾アルギネートのようなポリサッカライドを含むポリマー
US6531154B1 (en) 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
PT1019111E (pt) 1998-04-27 2002-10-31 Surmodics Inc Revestimento que liberta um agente bioactivo
US6376742B1 (en) 1999-02-17 2002-04-23 Richard J. Zdrahala In vivo tissue engineering with biodegradable polymers
WO2000051662A1 (en) 1999-03-04 2000-09-08 Tepha, Inc. Bioabsorbable, biocompatible polymers for tissue engineering
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
EP1611233B1 (en) * 2003-04-08 2016-01-06 Yeda Research And Development Co., Ltd. Stem cells having increased sensitivity to sdf-1 and methods of generating and using same
SE0302559D0 (sv) * 2003-09-25 2003-09-25 Astrazeneca Ab Method
AU2004280616A1 (en) * 2003-10-08 2005-04-21 Vet-Stem Inc. Methods of preparing and using stem cell compositions and kits comprising the same
US9598669B2 (en) * 2005-12-29 2017-03-21 Anthrogenesis Corporation Composition for collecting placental stem cells and methods of using the composition
US20100247512A1 (en) * 2006-03-31 2010-09-30 The Regents Of The University Of Michigan Pericellular Collagenase Directs the 3-Dimensional Development of White Adipose Tissue
ES2392729T5 (es) * 2007-09-19 2015-08-28 Pluristem Ltd. Células adherentes de tejidos adiposos o de placenta y uso de las mismas en terapia
US8222206B2 (en) * 2008-03-04 2012-07-17 Taiwan Advance Bio-Pharm Inc. Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H
JP5572291B2 (ja) * 2008-04-07 2014-08-13 独立行政法人国立長寿医療研究センター 歯髄及び/又は象牙質形成促進のための薬剤及びその利用
WO2010038610A1 (ja) * 2008-09-30 2010-04-08 オリエンタル酵母工業株式会社 新しい軟骨細胞増殖及び分化誘導剤
JP5905446B2 (ja) * 2010-03-24 2016-04-20 ライフネット ヘルス Bmp−4ペプチドおよび使用方法
WO2012027721A2 (en) * 2010-08-27 2012-03-01 Gilead Biologics, Inc Antibodies to matrix metalloproteinase 9

Also Published As

Publication number Publication date
MX2015014053A (es) 2016-04-07
KR20160006694A (ko) 2016-01-19
PH12015502306A1 (en) 2016-02-15
CA2908739A1 (en) 2014-10-09
US20160053250A1 (en) 2016-02-25
WO2014165780A2 (en) 2014-10-09
AU2014248002A1 (en) 2015-11-19
EP2981276A4 (en) 2017-03-22
WO2014165780A3 (en) 2014-12-18
RU2015147878A (ru) 2017-05-10
CR20150603A (es) 2016-04-04
HK1221405A1 (zh) 2017-06-02
JP2016520550A (ja) 2016-07-14
EP3290047A1 (en) 2018-03-07
CN105246500A (zh) 2016-01-13
EP2981276A2 (en) 2016-02-10
SG11201508199QA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
PH12015502306A1 (en) Matrix metalloproteinases and uses thereof
BRPI0411856A (pt) composições e métodos para o aumento da atividade de telomerase
DE69030880D1 (de) Zusammensetzung zur Stimulierung des Immunsystems
Ansari et al. A time course of NADPH-oxidase up-regulation and endothelial nitric oxide synthase activation in the hippocampus following neurotrauma
WO2005044179A3 (en) Formulations containing astragalus extracts and uses thereof
BR9812048A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos de tratar uma doença mediada por uma cinase, de tratar a rejeição no transplante de órgão, e de tratar a alopecia induzida pela quimioterapia
JP2016520550A5 (cg-RX-API-DMAC7.html)
DE60122672D1 (de) Zusammensetzung zur intestinalen verabreichung
BR112020024412A8 (pt) Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
IS5484A (is) Samsetning með azelaínsýru
BR0016304A (pt) Formulação de solução aquosa de interferon estável, método de preparação e usos para a mesma
DE502004008793D1 (cg-RX-API-DMAC7.html)
AR044315A1 (es) Agente para prevenir y/o tratar enfermedades acompañadas de alteraciones de tejidos que comprende un polipeptido
KR20160001102A (ko) 그라비올라 한방 추출물을 포함하는 모발 화장료 조성물
NO850391L (no) Preparater for kosmetisk, helse- og kroppskonserverende bruk
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
EP1108429A3 (en) An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases
DE60115622D1 (de) Methoden und zusammensetzungen zur aufklärung von proteinexpressionsprofilen in zellen
Borges et al. Are proteases used as anti-inflammatory agents in reality accelerating the inflammatory process?
KR102257532B1 (ko) 성장인자 복합체를 포함하는 레이저 치료 후 피부 재생용 조성물
DE69931148D1 (de) Behandlung von hiv infektionen
MX2024010492A (es) Anticuerpos humanos contra la proteína c activada y sus usos
WO2023122666A3 (en) Compounds and methods for modulating glycogen synthase 1
BRPI0403271A (pt) composição de liberação in vivo

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]